Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Market Analysis & Valuation

UpdatedFeb 25, 2026
DataAggregated Company Financials
Companies207
  • 7D1.1%
  • 3M9.0%
  • 1Y6.6%
  • YTD5.1%

The market is up 1.1% over the last week, with the Healthcare sector leading the way, up 1.2%. The market is up 6.0% over the last 12 months. Earnings are forecast to grow by 10% annually.

Market Valuation and Performance

Has the Swiss Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Feb 2026CHF 2.1tCHF 793.7bCHF 116.9b20.8x17.7x2.6x
Fri, 23 Jan 2026CHF 2.0tCHF 796.1bCHF 114.7b20.8x17.5x2.5x
Sun, 21 Dec 2025CHF 2.0tCHF 797.9bCHF 114.4b20.2x17.3x2.5x
Tue, 18 Nov 2025CHF 1.9tCHF 803.0bCHF 114.8b19.2x16.5x2.4x
Thu, 16 Oct 2025CHF 1.9tCHF 773.5bCHF 90.1b19.5x21x2.4x
Sat, 13 Sep 2025CHF 1.9tCHF 774.2bCHF 90.0b19.4x20.7x2.4x
Mon, 11 Aug 2025CHF 1.8tCHF 777.3bCHF 89.7b20.8x20.3x2.3x
Wed, 09 Jul 2025CHF 1.8tCHF 784.5bCHF 106.7b20.3x17x2.3x
Fri, 06 Jun 2025CHF 1.8tCHF 785.2bCHF 106.4b20.4x17.3x2.3x
Sun, 04 May 2025CHF 1.8tCHF 837.1bCHF 158.2b19.6x11.5x2.2x
Tue, 01 Apr 2025CHF 1.8tCHF 851.0bCHF 159.0b19.7x11.6x2.2x
Thu, 27 Feb 2025CHF 1.9tCHF 810.9bCHF 117.0b21.4x16.4x2.4x
Sat, 25 Jan 2025CHF 1.8tCHF 817.5bCHF 117.7b21.4x15.6x2.2x
Mon, 23 Dec 2024CHF 1.7tCHF 812.8bCHF 117.3b20.6x14.6x2.1x
Wed, 20 Nov 2024CHF 1.7tCHF 809.9bCHF 117.0b19.6x14.7x2.1x
Fri, 18 Oct 2024CHF 1.8tCHF 806.4bCHF 114.4b21.3x16x2.3x
Sun, 15 Sep 2024CHF 1.8tCHF 802.4bCHF 113.9b21x15.8x2.2x
Tue, 13 Aug 2024CHF 1.8tCHF 802.6bCHF 136.5b21.1x13.1x2.2x
Thu, 11 Jul 2024CHF 1.8tCHF 802.6bCHF 125.8b21.3x14.5x2.3x
Sat, 08 Jun 2024CHF 1.8tCHF 801.1bCHF 125.6b22x14.6x2.3x
Mon, 06 May 2024CHF 1.7tCHF 797.8bCHF 125.2b21.3x13.7x2.1x
Wed, 03 Apr 2024CHF 1.8tCHF 768.3bCHF 97.2b21.7x18.1x2.3x
Fri, 01 Mar 2024CHF 1.7tCHF 790.1bCHF 111.4b19.9x15.4x2.2x
Sun, 28 Jan 2024CHF 1.7tCHF 765.2bCHF 109.7b17.9x15.6x2.2x
Tue, 26 Dec 2023CHF 1.7tCHF 763.3bCHF 109.8b18.4x15.3x2.2x
Thu, 23 Nov 2023CHF 1.6tCHF 772.2bCHF 111.5b17.8x14.7x2.1x
Sat, 21 Oct 2023CHF 1.6tCHF 759.1bCHF 100.3b17.6x15.6x2.1x
Mon, 18 Sep 2023CHF 1.7tCHF 751.5bCHF 99.5b18.7x16.9x2.2x
Wed, 16 Aug 2023CHF 1.7tCHF 745.9bCHF 75.2b18.3x22.1x2.2x
Fri, 14 Jul 2023CHF 1.7tCHF 748.2bCHF 76.0b19.3x22.4x2.3x
Sun, 11 Jun 2023CHF 1.7tCHF 787.1bCHF 82.6b19.3x20.9x2.2x
Tue, 09 May 2023CHF 1.8tCHF 785.4bCHF 81.4b19.3x21.9x2.3x
Thu, 06 Apr 2023CHF 1.7tCHF 778.1bCHF 69.1b19.4x25.1x2.2x
Sat, 04 Mar 2023CHF 1.7tCHF 783.8bCHF 70.1b19.4x24.7x2.2x
Price to Earnings Ratio

24.7x


Total Market Cap: CHF 1.7tTotal Earnings: CHF 70.1bTotal Revenue: CHF 783.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Market Price to Earnings3Y Average 17.3x202420252026
Current Market PE
  • Investors are relatively neutral on the Swiss market at the moment, indicating that they expect earnings will grow in line with historical growth rates.
  • The market is trading close to its 3-year average PE ratio of 17.3x.
Past Earnings Growth
  • The earnings for Swiss listed companies have grown 19% per year over the last three years, while revenues have remained steady.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Sector Trends

Which sectors have driven the changes within the Swiss Market?

CH Market1.11%
Materials4.85%
Consumer Staples4.62%
Consumer Discretionary2.65%
Tech2.62%
Telecom1.75%
Real Estate0.98%
Industrials0.38%
Healthcare0.15%
Financials-0.63%
Utilities-1.82%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 30.1x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 19.3%, which is higher than its past year's earnings growth of 1.8% per year.
  • The Financials sector is the least preferred by investors for future growth, which is trading below its 3-year average of 8.0x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 19% over the next 5 years.
  • This is better than its past earnings growth rate of 1.8% per year.
  • In contrast, the Real Estate sector is expected to see its earnings decline by 10% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NESN NestléCHF 82.945.0%
+CHF 10.0b		-6.8%PE23.6xConsumer Staples
ROG Roche HoldingCHF 374.001.3%
+CHF 3.8b		25.0%PE23.1xHealthcare
AMRZ AmrizeCHF 50.1413.7%
+CHF 3.3b		n/aPE30.3xMaterials
CFR Compagnie Financière RichemontCHF 163.603.1%
+CHF 2.9b		-8.8%PE27.6xConsumer Discretionary
NOVN NovartisCHF 129.601.0%
+CHF 2.3b		28.7%PE22.9xHealthcare
See more

Market Insights

Header cover image
Alternatives part 2: 2026 and beyond 🔭
Richard Bowman avatar
Richard Bowman
|
|
Deep dive into the exciting world of Private Equity, Real Estate, Private Credit, Infrastructure & Transport and Hedge Funds.
Continue reading
Dotcom Bubble vs. Now 🫧
Last Week

Dotcom Bubble vs. Now 🫧

Latest News

BEAN
CHF 813.00
BELIMO Holding
7D
-8.1%
1Y
32.2%
BANB
CHF 56.95
Bachem Holding
7D
-10.5%
1Y
-2.2%
PGHN
CHF 852.60
Partners Group Holding
7D
-9.6%
1Y
-35.7%
NOVN
CHF 129.60
Novartis
7D
1.0%
1Y
28.7%

NOVN: Autoimmune Pipeline Readouts And Dividend Growth Will Shape Balanced Future Returns

Analysts have raised their Novartis price target from CHF 113.58 to CHF 116.24. This reflects updated assumptions that combine slightly higher revenue growth with a modestly lower profit margin and a higher future P/E multiple.
HOLN
CHF 74.30
Holcim
7D
4.8%
1Y
-21.0%

HOLN: Rich P/E And Downgrade Will Likely Limit Further Upside

Holcim's analyst price target has shifted to CHF 80, up CHF 5, as analysts weigh mixed revisions that balance slightly softer revenue and margin assumptions with a higher assumed future P/E multiple and recent price target changes at Citi and RBC Capital. Analyst Commentary Recent research on Holcim sends a mixed signal, with some bearish analysts trimming expectations while others adjust targets higher.
STMN
CHF 90.86
Straumann Holding
7D
-5.7%
1Y
-27.1%
NESN
CHF 82.94
Nestlé
7D
5.0%
1Y
-6.8%
ZURN
CHF 576.40
Zurich Insurance Group
7D
2.2%
1Y
-2.1%

ZURN: Future Returns Will Rely On Dividend Visibility And Slightly Firmer P/E Assumptions

Analysts have adjusted their price target for Zurich Insurance Group to CHF 574.78 from CHF 563.37, reflecting updated assumptions around revenue growth, profit margins and the future P/E multiple. What's in the News Zurich Insurance Group AG declared an annual dividend of CHF 30.0000 per share, scheduled to be paid on April 14, 2026, setting out a clear cash return timetable for shareholders (Key Developments).
ROG
CHF 374.00
Roche Holding
7D
1.3%
1Y
25.0%

ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead

Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
SDZ
CHF 65.64
Sandoz Group
7D
-2.3%
1Y
62.8%
AMRZ
CHF 50.14
Amrize
7D
13.7%
1Y
n/a
ABBN
CHF 70.62
ABB
7D
1.2%
1Y
44.2%

ABBN: Data Center Dependence Will Test Execution As Expectations Remain Elevated

Analysts have raised their ABB fair value estimate to CHF 62.40. The revision is supported by higher assumed revenue growth, a slightly increased discount rate, firmer profit margin expectations, a higher future P/E, and recent CHF 5 price target increases from several banks.
UBSG
CHF 31.76
UBS Group
7D
-2.3%
1Y
5.6%

UBSG: Higher P/E Expectations Will Drive Future Repricing Versus Political Breakup Risk

Analysts have revised their CHF based price target for UBS Group upward to reflect a higher estimated fair value of about CHF 50.79, with recent Street research pointing to adjusted views on revenue growth, profit margins and future P/E assumptions following mixed target moves at Citi, JPMorgan and Morgan Stanley, as well as a fresh downgrade at Goldman Sachs. Analyst Commentary Recent Street research on UBS Group reflects a mix of optimism and caution, with several price target revisions and one high profile downgrade shaping how investors are thinking about the shares.
GALD
CHF 144.10
Galderma Group
7D
-6.4%
1Y
29.1%

GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction

Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.
LONN
CHF 523.80
Lonza Group
7D
-2.3%
1Y
-9.4%
CFR
CHF 163.60
Compagnie Financière Richemont
7D
3.1%
1Y
-8.8%